Kornimate/medical-research-clean huggingface dataset:
examining measurement of behavioral neglect post stroke

Conditions: Stroke; Hemispatial Neglect

Summary: the purpose of this study is to examine measurement of unilateral neglect post stroke. although a number of clinical assessments are used to measure neglect, it is unclear whether items from some of the most commonly used assessments are able to effectively and comprehensively measure neglect. this study will determine whether these assessments measure different aspects of neglect and whether items from various neglect assessments can be combined to more effectively measure neglect.

many individuals have difficulty attending to the affected side of their body or to the affected side of space after stroke (unilateral neglect). although a number of clinical assessments are used to measure this inattention, it is unclear whether items from some of the most commonly used assessments are able to effectively and comprehensively measure inattention. clinical assessments provide critical information to clinicians and researchers and are used to inform treatment and document patient progress. therefore, it is important that investigators more closely examine these existing assessments. individuals who demonstrate impaired attention to the affected side after stroke also have greater motor impairment than individuals who do not have impaired attention, but investigators do not know how inattention affects reaching movements using the impaired arm. this study will examine various methods used to assess inattention to the affected side after stroke and also examine how inattention affects reaching movements of the impaired arm.

Eligibility criteria:
inclusion criteria: * unilateral hemispheric stroke * 18 years or older exclusion criteria: * severe aphasia * inability to follow 2-step directions * presence of other neurological disease that may impair vision or perception during performance of evaluation procedures

Keywords: stroke neglect rehabilitation
carefor: precision medicine driving precision nutrition for the treatment of neoadjuvant breast cancer

Conditions: Breast Carcinoma

Summary: the purpose of the study is to determine if a targeted dietary change can enhance the effect of neo-adjuvant chemotherapy

primary objective: i to determine if dietary alternations designed to downregulate the dominate molecular drivers of an individuals' breast cancer will enhance the effect of neoadjuvant chemotherapy and allow for an increase in the pathologic complete response rate. secondary objectives i) investigator measurable changes to molecular and patient characteristics from precision nutrition to determine a metric for evaluation this treatment in future studies.

Eligibility criteria:
inclusion criteria: * pathologically proven invasive breast cancer * planned neoadjuvant chemotherapy determined by the judgment of the medical oncologist * the patient must be female * age ≥ 18 * non-metastatic and non-inflammatory breast cancer * history/physical examination, including breast exam and documentation of weight and karnofsky performance status of 80-100% for at least 60 days prior to study entry. * women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during chemotherapy * patient must capable of and provide study specific informed consent prior to study entry * bmi ≥21 * weight ≥120lbs * no prior history of non-breast malignancies in the past 1 year unless it was a non- melanomatous skin lesion or carcinoma in situ of the cervix. * patient must not have acquired immune deficiency syndrome (aids) or hiv positive based upon current cdc definition; note, however, that hiv testing is not required for entry into this protocol. the need to exclude patients with aids or hiv from this protocol is necessary because anti-retrovirals may alter patient metabolism. * patient may not have any active gastrointestinal/malabsorption disorder at the discretion of the principal investigator which may include: * chronic pancreatitis * chronic diarrhea or vomiting * active eating disorder * no history of or current active drug/alcohol dependence. * no patients with decisional impairment. exclusion criteria: * patient is male. * age \<18 years * clinical stage iv cancer * inflammatory breast cancer (t4d) * women of childbearing potential with a positive serum beta hcg. * decision impaired patients. * bmi \< 21 * weight \< 120lbs * weight loss ≥10% in the last 3 mos * prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 1 year prior to registration * non-epithelial breast malignancies such as sarcoma or lymphoma * active gastrointestinal/malabsorption disorder at the discretion of the principal -investigator which may include: * chronic diarrhea or vomiting * active eating disorder * active drug/alcohol dependence or abuse history.
rhizarthrosis study

Conditions: Rhizarthrosis

Summary: rhizarthrosis is the wear of the thumb saddle joint. it is a very common disease affecting up to 25% of postmenopausal women. there are currently various conservative and surgical methods available for treatment. if conservative treatment does not lead to freedom from pain, one of the surgical methods can be used, such as metacarpal extension osteotomy, trapeziectomy with or without ligamentoplasty, trapeziometacarpal arthrodesis, prosthesis implantation and various forms of interposition arthroplasty . despite the high satisfaction rate of up to 95% after surgical treatment, the anatomy of the carpus is irreversibly destroyed . apart from that, these operations are also associated with corresponding complications and post-operative immobilization of several weeks. thus, a minimally invasive treatment method with a corresponding success rate would be of great advantage. hypothesis: by infiltrating and filling the joint with platelet-rich plasma (prp), fat or a combination of both, the pain of rhizarthrosis can be reduced. aim of the study: the aim of the announced doctoral thesis is to investigate the effect of prp, lipofilling and its combination on arthroses of the thumb saddle joint after a single joint injection and to compare it with a control group.it is to be proven that prp, fat and their combination lead to a different degree of pain relief compared to the control group due to the expansion of the joint space and the associated filling effect.


Eligibility criteria:
inclusion criteria: * diagnosed rhizarthrosis exclusion criteria: * pregnancy and breastfeeding * no signed informed consent

Keywords: rhizarthrosis
expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (hrpc)

Conditions: Prostate Cancer

Summary: the spera trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (hrpc) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral satraplatin in this patient population.

\*\*\*\*\*update\*\*\*\*\* on october 30th, 2007 gpc biotech announced topline overall survival results for the phase iii trial in hormone refractory prostate cancer-satraplatin and prednisone against refractory cancer (sparc) trial. the trial evaluated satraplatin plus prednisone versus placebo plus prednisone as a second-line treatment in 950 patients with hormone-refractory prostate cancer (hrpc). the companies reported that the trial did not achieve the endpoint of overall survival (p=0.80, stratified log rank analysis). the median was 61.3 weeks for the satraplatin arm compared to 61.4 weeks for the control group and the hazard ratio was 0.97 (95% ci: 0.83, 1.13). the companies are currently conducting pre-specified subset analyses. satraplatin is a member of the platinum-based class of chemotherapy drugs. platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

Eligibility criteria:
inclusion criteria: * metastatic(stage d2)prostate cancer * progression after unlimited prior cytotoxic chemotherapy regimens * ecog performance status equal/less than 2 * surgical or medical castration * adequate bone marrow, liver, and renal function * informed consent * patients treated with bisphosphonates prior to entry are eligible and should continue bisphosphonates therapy while on this trial exclusion criteria: * serious concurrent uncontrolled medical disorder * malignant disease requiring on-going therapy * prior significant rt/radionuclide therapy * major gi surgery or gi disease affecting absorption * disease where corticosteroids are contraindicated * brain metastases * poorly-controlled or uncontrolled insulin-dependent diabetes

Keywords: hormone refractory prostate cancer (hrpc) hormone refractory prostate cancer unlimited prior cytotoxic chemotherapy regimens
comparison trial of opa-15406 ointment in adult patients with atopic dermatitissyndrome

Conditions: Atopic Dermatitis

Summary: to demonstrate the superiority of imp (1% opa-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in investigator's global assessment (iga) at week 4 as the primary endpoint in adult patients with ad.


Eligibility criteria:
inclusion criteria: * diagnosis of ad based on the japanese dermatological association's criteria * history of ad for at least 3 years * atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of body surface area (bsa, excluding scalp) at the screening and baseline examinations * iga score of 2 or 3 at the screening and baseline examinations exclusion criteria: * subjects who have an ad or contact dermatitis flare-up defined as a rapid intensification of ad, within 28 days prior to the baseline examination
advancing suicide intervention strategies for teens during high risk periods

Conditions: Suicide Attempts; Suicidal Ideation; Suicide and Self-harm; Suicide Threat

Summary: to inform the effective management of adolescent suicide risk by evaluating promising treatments and developing the evidence-base for interventions that are well suited for widespread adoption, sustained quality, and impact.

the current study aims to evaluate safety planning intervention with follow-up (spi+), collaborative assessment and management of suicidality (cams) and usual care. adolescents, parents, and clinicians will participate in the project to advance to following research aims: 1) assess the comparative effectiveness of cams and spi+ compared to usual care, 2) evaluate the mechanism of change accounting for the therapeutic effects of the interventions 3) identify moderators of treatment effects. participants and their parents will receive study assessments at baseline, 2-week, 1-month, 2-month, 6-month, and 12-month timepoints. study assessments will ask about participant demographics (sample characterization), suicide attempts, suicidal ideation, non-suicidal self-injury, service utilization, self-assessed risk, treatment integrity, sleep, family cohesion, and social experiences. youth participants and their legal guardian both consent to participate in the research procedures.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. youth, aged 11-17 3. endorse suicidal ideation and/or behavior 4. admitted to acute care (emergency, inpatient medical or inpatient psychiatric) due to suicidality exclusion criteria: 1. presence of psychosis, intellectual disability, autism spectrum disorder, eating disorder with unstable vitals 2. limited english proficiency that would interfere with the ability to complete study assessments
zanubrutinib plus r-chop for patients with newly diagnosed untreated non-gcb dlbcl

Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Summary: aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with r-chop for newly diagnosed untreated non-gcb dlbcl patients

diffuse large b-cell lymphoma (dlbcl) is the most common type of non-hodgkin's lymphoma. according to hans' algorithms, dlbcl can be identified as 2 subtypes: germinal b-cell-like(gcb) and non-germinal b-cell-like(non-gcb). approximately 50 to 60% of dlbcl was non-gcb subtype dlbcl.the non-gcb dlbcl revealed poor clinical outcomes. bruton's tyrosine kinase (btk) inhibitors have established therapeutic activity in b cell malignancies, with potential activity in non-gcb dlbcl. this study will evaluate the efficacy and safety of zanubrutinib in combination with r-chop for newly diagnosed untreated non-gcb dlbcl patients.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed non-gcb dlbcl with extrinsic involvement 2. age ≥ 18 years 3. measurable disease of at least 15mm(node)/10mm（extranodal） 4. ecog performance status 0-2 5. adequate organ function:cardiac ejection fraction (ef) ≥ 50%;creatinine clearance rate (≥30 ml/min) of serum creatinine; aspartate aminotransferase (ast), alanine aminotransferase (alt) ≤3 times uln 6. adequate bone marrow function:platelet count (≥ 50×10\^9/l);hemoglobin (≥ 8 g/dl);the absolute value of neutrophils (≥1.0×10\^9/l) 7. estimated survival time ≥3 months 8. subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study exclusion criteria: 1. accepted major surgery within 4 weeks before treatment; 2. diagnosis of primary mediastinal lymphoma or primary cns lymphoma; 3. previous history of indolent lymphoma; 4. prior malignancy (other than dlbcl), except for cured malignant tumors with no active lesions for 3 years;adequate treatment of inactive lesions in non-melanoma skin cancer 、malignant tonsilloma or carcinoma in situ; 5. history of intracranial haemorrhage in preceding 6 months,requires or receiving anticoagulation with warfarin or equivalent antagonists; 6. requires treatment with a strong/medium cyp3a inducer; 7. the previous use of anthracycline-based drugs \> 150 mg/m2; 8. evidence of complications or medical conditions, including but not limited, that may interfere the conduct of the study or place the patient at serious risk:significant cardiovascular disease(class 3 or 4 cardiac disease as defined by the new york heart association functional classification、myocardial infarction within 6 months of screening、uncontrolled or symptomatic arrhythmias) and/or significant lung disease; 9. hiv infection and/or active hepatitis b or active hepatitis c; 10. uncontrolled systemic infection; 11. pregnant or breasting-feeding women; 12. according to the researchers' judgment, patients' underlying condition may increase their risk of receiving research drug treatment, or confuse their judgment on toxic reactions.

Keywords: zanubrutinib, r-chop, newly diagnosed non-gcb dlbcl
fluorescent imaging & methylene blue: ureter study

Conditions: Ureteric Injury; Surgery; Surgery--Complications

Summary: the main aim of this project is to assess whether intravenous methylene blue can help identify the ureters during open and laparoscopic (keyhole) surgery. the ureters are small tubes that link the kidney to the bladder and, if not properly identified during surgery, may be damaged. methylene blue has been safely given to patients for many years and it is fluorescent. it is removed by the kidney and will therefore travel through the ureters. methylene blue shines brightly (becomes fluorescent) when viewed under red light. this study aims to compare the ability of methylene blue with white light to identify the location of the ureters during colorectal surgery. recruitment will include 50 patients undergoing colorectal surgery (25 for keyhole/laparoscopic, 25 for open procedures). each patient will act as their own control. to detect the fluorescence, a special fluorescent laparoscope for keyhole surgery will be utilised, and a wide-field camera will be used for open surgery. the potential benefits of this procedure are to identify the ureters during surgery and therefore prevent inadvertent damage to them it is hoped that near infra-red light emitting from the ureters will be detected. this will allow the surgeon to determine the anatomy of the ureters during the operation and avoid inadvertent injury. funding source: nuffield department of surgical sciences, university of oxford recruitment sites: oxford university hospitals nhs trust.


Eligibility criteria:
inclusion criteria * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * patients undergoing laparoscopic or open colorectal surgery * in the investigator's opinion, is able and willing to comply with all study requirements. exclusion criteria the participant may not enter the study if any of the following apply: * patient who is unable or unwilling to give informed consent * female participant who is pregnant, lactating or planning pregnancy during the course of the trial. * significant renal or hepatic impairment. * any patients with previous allergies to methylene blue * any patients at risk of serotonin syndrome, including those taking serotonin reuptake inhibitors (ssris) or serotonin reuptake inhibitors (e.g. duloxetine, sibutramine, venlafaxine, clomipramine, imipramine) * patients with glucose-6-phosphate dehydrogenase (g6pd deficiency)

Keywords: ureteric injury colorectal surgery
factorial trial of antimicrobial therapy and/or catheter change for catheter urinary tract infections.

Conditions: Urinary Tract Infections

Summary: urinary tract infection (uti) is a common infection in patients in the intensive care unit (icu) that increases length of stay but not mortality. it is not known whether antibiotic treatment will alter outcomes. our previous studies have documented wide practice variations exist amongst doctors, including prescribing antibiotics to asymptomatic patients. therefore, the merits of various ways to manage the infection require further studies to minimize the potential for over-prescribing of antibiotics, a practice that can increase the development of resistant bacteria. the objective of this pilot study is to determine the feasibility of conducting a larger definitive study that will determine the effect of catheter change and/or systemic antibiotics as compared to no interventions on outcomes and resource utilization in icu patients with uti. patients will be randomized to receive no treatment, antibiotics alone, urine catheter change alone, and both catheter change and antibiotics. their clinical outcomes will be assessed. results from the pilot trial will provide information about whether it is feasible to conduct the larger definitive trial. results of the definitive study will provide guidance to clinicians on how to manage a frequent clinical problem and optimize antibiotic usage.


Eligibility criteria:
inclusion criteria: 1. adult icu patient (≥ 18 years old) 2. admitted to the icu for ≥ 96 hours 3. indwelling urinary catheter in place for ≥ 48hours that was inserted during this hospital admission 4. urine culture positive (≥ 105 cfu/ml) for 1 or 2 organism (s) (e.g. bacteria or fungus) 5. have received antimicrobial therapy that would cover the isolated organism(s) in the index urine culture for \< 24 hours (i.e. therapy that does not cover the isolated organism(s) in the index urine culture of any duration or antimicrobial that covers the index urine organism for \< 24 hours are permitted) exclusion criteria: 1. suspected or confirmed pyelonephritis, renal abscess, or concurrent bacteremia with the same organism(s) as those isolated in the index urine culture 2. anuria (\< 50 ml/day) 3. imminent death within 48 hours or decision to withdraw supportive care by clinical team 4. neutropenia (\< 500/mm3) 5. patient has an alternative infection and requires an antimicrobial that has a spectrum of activity which include all the organism(s) isolated from the index urine culture 6. mixed fungal/bacterial cauti (i.e. index urine culture contains both bacteria and fungus)

Keywords: urinary tract infection critically ill icu antimicrobial catheter associated urinary tract infections
establishing predictors of enlarged prostate treatment adherence: linking symptom improvement to adherence

Conditions: Prostatic Hyperplasia

Summary: patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ari) therapy, alpha-blocker (ab) therapy, or combination therapy for enlarged prostate (ep). adherence with ep therapy will be evaluated. the researchers believe that the majority of participants will report that they are compliant with therapy. the data source is a cross-sectional patient survey administered at one time point.


Eligibility criteria:
inclusion criteria: * males * aged 50 years or older * residents of the united states * receiving a prescription for an enlarged prostate (ep) treatment within 12 months prior to survey initiation exclusion criteria: * patients with prostate cancer * no health/prescription insurance * patients receiving medication(s) for ep on a prn basis

Keywords: enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, adherence
effect of carvedilol rapid up-titration in patients with heart failure with reduced ejection fraction

Conditions: Heart Failure With Reduced Ejection Fraction HFrEF

Summary: guidelines-directed medical therapy has improved dramatically outcomes in heart failure with reduced ejection fraction (hfref) patients. beta-blockers have the most beneficial effects on all caused mortality and rehospitalization on hfref, but unfortunately, since the discovery of beta-blocker therapy in hfref, there was no change in the way of titration, start low go slow, which resulted in difficulties in reaching optimal doses for some patients.

this study is a randomized controlled trial, single-center study in hfref patients, that held in universitas sebelas maret hospital, central java, indonesia. the investigators divided 26 hfref patients consecutively into two groups, the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. and the second group will have carvedilol titration according to established guidelines on heart failure, start 3.125mg twice daily, and up titrated every 2 weeks. every patient will be checked for il-6, tnf-α, nt-probnp, mda, left ventricular ejection fraction, six minutes walking test, and kansas city cardiomyopathy questionnaire on day 1, pre-discharge, and one month after hospitalization. the study was approved by the university ethics committee. the clinical parameters evaluated at admission were analyzed using variable comparative with shapiro wilk or one-way anova, with three intervals analysis using repeated anova (p\<0.05).

Eligibility criteria:
inclusion criteria: * acute heart failure patient with reduced ejection fraction in universitas sebelas maret hospital with naive betablocker therapy * age \>18 years old * initial heart rate \> 50 bpm exclusion criteria: * cardiogenic shock * septicaemia * high degree av block or on pace maker * history of beta blocker intolerance * reactive pulmonary disease * severe peripheral artery disease * creatinine level \> 2.5 mg/dl * potassium serum \>5 mmol/l

Keywords: hfref carvedilol rapid uptitration heart failure
effects of muscle fatigue and kinesio taping on shoulder position sense

Conditions: Fatigue; Proprioception

Summary: the purpose of this study is to investigate the effects of kinesio taping on the position sense of shoulder after muscle fatigue.


Eligibility criteria:
inclusion criteria: * healthy participants exclusion criteria: * prior shoulder surgery * shoulder injury that required rehabilitation in the last 2 years * shoulder dislocation * ligamentous laxity

Keywords: fatigue proprioception shoulder